MVA/HIV62B vaccine / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Combinatorial Therapy to Induce an HIV Remission (clinicaltrials.gov) - P1/2 | N=11 | Active, not recruiting | Sponsor: University of California, San Francisco | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Combinatorial Therapy to Induce an HIV Remission (clinicaltrials.gov) - P1/2 | N=11 | Active, not recruiting | Sponsor: University of California, San Francisco | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Active, not recruiting ➔ Completed; Trial completion date: Feb 2020 ➔ Oct 2019

Clinical • Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • PCR

Combinatorial Therapy to Induce an HIV Remission (clinicaltrials.gov) - P1/2 | N=11 | Active, not recruiting | Sponsor: University of California, San Francisco | Recruiting ➔ Active, not recruiting | N=20 ➔ 11

Enrollment change • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. (PubMed, Vaccine) - "Late boosting with AIDSVAX, alone or in combination with MVA, can broaden binding antibody responses and increase T-cell responses even years following the original MVA/HIV62B with or without DNA-priming vaccine."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=100; Not yet recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Clinical • New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=100; Active, not recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Trial completion date: Sep 2019 ➔ Feb 2020

Clinical • Trial completion date • Human Immunodeficiency Virus • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Completed ➔ Active, not recruiting; Trial completion date: Aug 2018 ➔ Sep 2019

Clinical • Enrollment closed • Trial completion date • Human Immunodeficiency Virus • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=100; Active, not recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Trial primary completion date: Apr 2018 ➔ Aug 2018

Clinical • Trial primary completion date • Human Immunodeficiency Virus • CD4 • CD8 • PCR

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Active, not recruiting ➔ Completed; N=100 ➔ 27; Trial completion date: Oct 2019 ➔ Aug 2018

Clinical • Enrollment change • Trial completion • Trial completion date • Human Immunodeficiency Virus • CD4 • CD8 • PCR

GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients (GlobeNewswire) - "GeoVax Labs, Inc....announced today initiation of a Phase 1 clinical study of a combination therapy in HIV-positive patients utilizing GeoVax’s novel boost component MVA62B....The study is designed to induce remission in HIV-positive individuals, also known as a 'functional cure.'...The single-arm, open-label study will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART)....MVA62B is the boosting component for GeoVax’s preventive HIV vaccine, GOVX-B11, which has successfully completed a Phase 2a clinical trial....We anticipate starting enrollment of patients in the near term."

Enrollment status • Trial status • Human Immunodeficiency Virus

GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) - "GeoVax will provide its novel MVA-VLP-HIV vaccine (MVA62B) for evaluation in an arm of the clinical trial in combination with AGT103-T. AGT has stated its intention to begin recruiting patients for the Phase 1 study in 2020....Patient enrollment for the clinical trial is expected to commence in late 2020.; HIV Vaccines (Preventive)...The Company is now planning for a new Phase 1 human clinical trial (designated HVTN 132) to further assess the safety, tolerability, and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11 in combination with protein boost vaccines. Management has expected that HVTN 132 would commence patient enrollment in late 2020, but now anticipates the trial to start during the first half of 2021..."

Trial initiation date • Human Immunodeficiency Virus

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); N=70 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal